Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation and Depletion (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of Depreciation and Depletion data on record, last reported at $27000.0 in Q3 2025.

  • For Q3 2025, Depreciation and Depletion rose 8.0% year-over-year to $27000.0; the TTM value through Sep 2025 reached $110000.0, up 22.22%, while the annual FY2024 figure was $96000.0, 43.28% up from the prior year.
  • Depreciation and Depletion reached $27000.0 in Q3 2025 per DNTH's latest filing, down from $30000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $30000.0 in Q2 2025 and bottomed at $6000.0 in Q3 2022.
  • Average Depreciation and Depletion over 4 years is $21083.3, with a median of $22500.0 recorded in 2024.
  • Peak YoY movement for Depreciation and Depletion: surged 200.0% in 2023, then grew 8.0% in 2025.
  • A 4-year view of Depreciation and Depletion shows it stood at $6000.0 in 2022, then skyrocketed by 233.33% to $20000.0 in 2023, then rose by 30.0% to $26000.0 in 2024, then rose by 3.85% to $27000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $27000.0 in Q3 2025, $30000.0 in Q2 2025, and $27000.0 in Q1 2025.